The state of Michigan currently has 20 active clinical trials seeking participants for Asthma research studies. These trials are conducted in various cities, including Ann Arbor, Detroit, Grand Rapids and Kalamazoo.
REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study
Recruiting
This is a prospective, real-world, single arm, global, multi-centre study to evaluate the effect of timely treatment with mepolizumab (NUCALA) to achieve clinical remission in adult participants with severe asthma with an eosinophilic phenotype (SA-EP).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: GSK Investigational Site, Ann Arbor, Michigan
Conditions: Asthma
A Study to Assess the Effect of Dexpramipexole in Participants With Severe Eosinophilic Asthma.
Recruiting
This study will assess the efficacy and safety of dexpramipexole as an adjunctive oral therapy in participants with inadequately controlled asthma with an eosinophilic phenotype and a history of asthma exacerbations.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
02/24/2025
Locations: Research Site 20001-006, Flint, Michigan +2 locations
Conditions: Eosinophilic Asthma, Asthma; Eosinophilic, Asthma
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)
Recruiting
The objective of this clinical study is to investigate the safety, tolerability, and efficacy of dexpramipexole in participants with inadequately controlled severe eosinophilic asthma.
Gender:
ALL
Ages:
Between 12 years and 99 years
Trial Updated:
02/24/2025
Locations: Research Site 30001-472, Farmington Hills, Michigan +2 locations
Conditions: Eosinophilic Asthma, Asthma; Eosinophilic, Asthma
Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma
Recruiting
This is a Phase 2b, global, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the efficacy, safety, and tolerability of add-on therapy with SC lunsekimig in adult participants aged 18 to 80 years, (inclusive) with moderate-to-severe asthma.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/16/2025
Locations: University of Michigan Health System - Ann Arbor- Site Number : 8400004, Ann Arbor, Michigan
Conditions: Asthma
Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics
Recruiting
The purpose of the study is to evaluate effect of benralizumab on structural and lung function changes in severe eosinophilic asthmatics. Changes will be assessed over 48 week treatment period in patients with persistent symptoms despite standard therapy of inhaled corticosteroids (ICS) plus long acting B2-agonist (LABA) with or without additional controller medication. Patients who complete treatment will enter 4 weeks follow-up period.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
02/12/2025
Locations: Research Site, Ann Arbor, Michigan +1 locations
Conditions: Asthma
Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care
Recruiting
ANCHOR is a prospective, multi-center, phase IV, interventional, single-arm, open-label study of 2,000 adult participants with symptomatic asthma requiring the use of rescue therapy aimed to compare the asthma exacerbation rates before and after switching from albuterol or levalbuterol to albuterol plus budesonide inhalation aerosol as rescue therapy.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
01/07/2025
Locations: Research Site, Ann Arbor, Michigan +1 locations
Conditions: Asthma
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
Recruiting
The purpose of this study is to compare the effect of budesonide/albuterol metered-dose inhaler (BDA MDI) with albuterol sulfate metered-dose inhaler (AS MDI), both administered as needed, on the annualized rate of severe asthma exacerbations in adolescents with a documented clinical diagnosis of asthma and at least one severe exacerbation in the prior year.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
12/19/2024
Locations: Research Site, Detroit, Michigan
Conditions: Asthma
Investigating Dupilumab's Effect in Asthma by Genotype
Recruiting
The Goal of this study is to investigate if individuals ages 12 years and older, carrying the IL-4RαR576 gene variant, will have a greater response to therapy acting directly on the anti-IL-4R. This will be conducted by examining the effect of a 48 week therapy with dupilumab on the rate of asthma exacerbations.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
11/22/2024
Locations: Henry Ford Health System, Detroit, Michigan
Conditions: Asthma